West Michigan Cancer Center, a collaboration of Borgess Health and Bronson Healthcare Group, has appointed Joseph Mirro, MD, to the dual role of Chief Executive Officer (CEO) and Chief Medical Officer (CMO). He replaces founding CEO Terry McKay, who will retire July 17th.
A distinguished pediatric oncologist and educator, Dr. Mirro brings to WMCC more than 35 years experience in oncology and healthcare leadership, most recently as Vice President of Cancer Services at Milwaukee, Wisconsin-based Aurora Health Care. Prior to that, he served as a pediatric oncologist, medical school professor and administrator at St. Jude Children’s Research Hospital in Memphis, Tennessee.
WMCC’s strong foundation and reputation for excellence in serving the cancer patients across Southwest Michigan drew Dr. Mirro to Kalamazoo. “I am excited to join the outstanding staff at WMCC and help provide the patients we serve with unsurpassed cancer care,” Mirro said. “I am honored to become associated with two excellent health care systems; and will do everything I can to advance the mission of both Bronson and Borgess so that every person in and around Kalamazoo can receive the best medical treatments available anywhere. Additionally, the opportunity to contribute to the academic mission of the new medical school makes this position at WMCC perfect”.
The search committee’s decision to select Dr. Mirro for the combined CEO/CMO position reflects WMCC’s continuing commitment to clinical excellence in cancer care. Frank Sardone, president and CEO of Bronson Healthcare, said he applauds current CEO Terry McKay for her many years of leadership and sees Dr. Mirro as the perfect choice as WMCC moves forward. “Dr. Mirro’s unique combination of administrative, clinical and academic leadership skills will enable him to make the most of this area’s superb medical resources. This is the right time for a physician leader to engage providers, academia and the hospitals in delivering world-class cancer care to our community.”
Current CEO Terry McKay has led the organization for 17 years, from its inception through its steady ascent to a top performing community cancer center. Today, WMCC averages nearly 80,000 patient visits annually and has earned numerous distinctions for clinical excellence. Paul Spaude, CEO of Borgess Health, said with McKay’s leadership, the community has been the beneficiary of technology usually available only at university research hospitals. “Over the years, Terry McKay has been a remarkable force,” said Spaude. “She’s grown the capabilities of the organization, and ensured the community always had every advantage that technology and talent would permit.”
Spaude added that McKay leaves the Cancer Center in an excellent position, poised and ready for a projected growth in patients due to the aging baby boom population. Teamwork, collaboration and a commitment to delivering the highest quality care to patients are the reasons WMCC is positioned for the future, according to McKay. “We are very fortunate to have such highly skilled, compassionate people, taking good care of every patient, every time, every day”, said McKay. “It has been an absolute joy to work with everyone and an honor to create an organization that I envision as the ultimate environment and culture to care for cancer patients. In 17 years, there was never a day that I didn’t enjoy coming to work,” added McKay.